Viela Bio: AstraZeneca Urges Chancery To Toss $3B Viela Bio Sale Suit
An attorney for AstraZeneca told a Delaware vice chancellor Tuesday that clinical stage biopharmaceutical company Viela Bio Inc. failed to show that AstraZeneca had the shares or clout needed to push through a purportedly underpriced $3 billion sale of the business in 2021.
Read full article »
Viela Bio is a Maryland-based biotechnology company that develops and commercializes therapeutics for autoimmune and severe inflammatory diseases.
Read more